Responses to Rh peptides by T cells from patients with CLL with secondary AIHA when different PBMC populations are used as APCs
. | . | Proportion of responses when PBMCs were used as APCs, % . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | Populations depleted from PBMCs . | . | . | Positively selected population . | |||
| CLL patient . | Rh peptide tested . | CD14+ . | CD14+, CD1a+/11c+ . | CD14+, CD1a+/11c+, CD5+ . | CD5+ . | |||
| 1 | D33 | NT | NT | 140 | 176 | |||
| 1 | D46 | NT | NT | 64 | 46 | |||
| 1 | D62 | 65 | 54 | 43 | 39 | |||
| 1 | D20 | 117 | 25 | 32 | NT | |||
| 1 | D27 | 116 | 63 | 39 | NT | |||
| 4 | D23 | 25 | 22 | 21 | 46 | |||
| 7 | ce20 | NT | NT | 47 | 59 | |||
| 8 | ce2 | 12 | NT | 64 | 114 | |||
| 8 | ce21 | NT | NT | 166 | 124 | |||
. | . | Proportion of responses when PBMCs were used as APCs, % . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | Populations depleted from PBMCs . | . | . | Positively selected population . | |||
| CLL patient . | Rh peptide tested . | CD14+ . | CD14+, CD1a+/11c+ . | CD14+, CD1a+/11c+, CD5+ . | CD5+ . | |||
| 1 | D33 | NT | NT | 140 | 176 | |||
| 1 | D46 | NT | NT | 64 | 46 | |||
| 1 | D62 | 65 | 54 | 43 | 39 | |||
| 1 | D20 | 117 | 25 | 32 | NT | |||
| 1 | D27 | 116 | 63 | 39 | NT | |||
| 4 | D23 | 25 | 22 | 21 | 46 | |||
| 7 | ce20 | NT | NT | 47 | 59 | |||
| 8 | ce2 | 12 | NT | 64 | 114 | |||
| 8 | ce21 | NT | NT | 166 | 124 | |||
PBMCs remaining after T-cell purification were fractionated by negative or positive selection into putative APC types, and all results are expressed as percentages of the response when the unfractionated PBMCs act as APCs. Sequential depletion of CD14+, CD1a+/11c+, and CD5+ cells removes monocytes, dendritic cells, and CLL cells, respectively.
NT indicates not tested.